返回
摘要
En 中文
Interleukin-10 (IL-10) is considered to be an immunosuppressive cytokine. However, the continuous administration of pegylated IL-10 (PEG-IL10) leads to the rejection of large, firmly established and metastatic syngeneic tumors. PEG-IL10 therapy induces the expansion and activation of intratumoral, tumor antigen-specific CD8(+) T cells, leading to interferon gamma (IFN gamma)-mediated Th1 like immunity and tumor rejection.
Keyword:
CD8 T cells
IL-10
cytotoxicity
intratumoral
tumor immune surveillance
cytokine therapy
AI总结
对已上传原文的论文进行重点信息的提取,主要内容包括:简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
6.3
论文数:
3.9K
被引数:
1.9W
机构
暂无机构信息
引用论文
Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naive Prostate Cancer Patients
CLINICAL CANCER RESEARCH
IF10.2
Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibodyCpG免疫刺激寡核苷酸和抗白细胞介素10受体抗体逆转肿瘤诱导的树突状细胞麻痹
The immune contexture in human tumours: impact on clinical outcome人类肿瘤的免疫环境: 对临床结果的影响
NATURE REVIEWS CANCER
IF66.8
没有更多内容

